1. Volume 55, Issue 2, Pages 334-347 (February 2009)
Phosphodiesterase Type 5 Inhibitors in Postprostatectomy Erectile Dysfunction: A Critical Analysis of the Basic Science Rationale and Clinical Application 
Konstantinos Hatzimouratidis, Arthur L. Burnett, Dimitrios Hatzichristou, Andrew R. McCullough, Francesco Montorsi, John P. Mulhall 
European Urology 
Volume 55, Issue 2, Pages (February 2009)
DOI: /j.eururo
Copyright © 2008 European Association of Urology Terms and Conditions

2. Fig. 1
The vicious cycle of post–radical prostatectomy erectile dysfunction.
European Urology  , DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

3. Fig. 2
Mean duration of tip rigidity >55% as a percentage of the baseline (preoperative) value, in responders (R) versus nonresponders (NR) and for sildenafil treatment (sildenafil 100mg or sildenafil 50mg) versus placebo. Because only one man in the placebo group was a responder, values for the placebo responder group should be interpreted with caution. Reprinted with permission from Blackwell Publishing [58].
European Urology  , DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

4. Fig. 3
Efficacy of vardenafil 10mg and vardenafil 20mg after bilateral nerve-sparing radical prostatectomy (BNSRP) and unilateral nerve-sparing radical prostatectomy (UNSRP) compared to placebo. The x-axis shows the weighted mean difference and 95% CI for (a) International Index of Erectile Function (IIEF) erectile function (EF) domain and (b) Sexual Encounter Profile question 3 (SEP3). Data are from Brock et al [90] and Miles et al [92]. The right part of the graph (right to the vertical line) supports the use of vardenafil in terms of efficacy while the left part supports the use of placebo (no efficacy).
European Urology  , DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

5. Fig. 4
Efficacy of tadalafil 20mg after bilateral nerve-sparing radical prostatectomy (BNSRP) compared to placebo. The x-axis shows the weighted mean difference and 95% CI for International Index of Erectile Function (IIEF) erectile function (EF) domains, odds ratio, and 95% CI for Sexual Encounter Profile question 2 (SEP2) and question 3 (SEP3). Data are from Montorsi et al [93] and Miles et al [92]. The right part of the graph (right to the vertical line) supports the use of tadalafil in terms of efficacy, while the left part supports the use of placebo (no efficacy).
European Urology  , DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions